Premium
1α(OH)D 3 (ETALPHA)® treatment and receptor studies in 16 patients with chronic and myeloproliferative disorders
Author(s) -
Wieslander Steen Bo,
Mortensen Børge T.,
Binderup Lise,
Nissen Nis I.
Publication year - 1987
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/j.1600-0609.1987.tb00160.x
Subject(s) - myelofibrosis , medicine , myeloproliferative disorders , alpha (finance) , gastroenterology , receptor , bone marrow , surgery , construct validity , patient satisfaction
10 patients with CLL and 2 with CML were treated with gradually increasing doses of 1α(OH)D 3 , up to 4 μg daily during 6 wk. 3 patients with preleukemia and 1 with myelofibrosis were treated with 2 μg daily of 1α(OH)D 3 for a prolonged period up to 17 wk. The treatment with 1α(OH)D 3 did not result in changes of disease parameters in any of the patients under study. Receptor studies for 1,25(OH) 2 D 3 were performed in 8 CLL patients and revealed only 1 patient with increased specific receptor binding capacity. The maximum tolerable dose of 1α(OH)D 3 varied individually, but was in the range of 2–4 μg daily.